Acrivon Therapeutics (ACRV) Prepaid Assets (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Prepaid Assets of $1.5 million for Q1 2026, down 12.35% year-over-year from $1.7 million in Q1 2025, and down 20.4% quarter-over-quarter from $1.9 million in Q4 2025.
Acrivon Therapeutics (ACRV) Prepaid Assets (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Prepaid Assets for 6 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 12.35% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 12.35% YoY), while the FY2025 annual figure was $1.9 million, down 13.31% from the prior year.
- Prepaid Assets slipped to $1.5 million in Q1 2026 per ACRV's latest filing, from $1.9 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $4.3 million in Q4 2022 and bottomed at $989000.0 in Q2 2025.
- Historically, Prepaid Assets has averaged $2.1 million across 5 years, with a median of $1.9 million in 2025.
- Annual changes were most pronounced in 2022 — Prepaid Assets soared 439.63% — and 2023, when it slumped 48.57%.
- Acrivon Therapeutics' Prepaid Assets stood at $4.3 million in 2022, then slumped by 48.57% to $2.2 million in 2023, then dropped by 3.8% to $2.1 million in 2024, then declined by 13.31% to $1.9 million in 2025, then declined by 20.4% to $1.5 million in 2026.
- Business Quant data shows ACRV's Prepaid Assets at $1.5 million in Q1 2026, $1.9 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Mn |
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 989,000.00 |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | 2.17 Mn |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 2.40 Mn |
| Jun 30, 2023 | 2.33 Mn |
| Mar 31, 2023 | 3.75 Mn |
| Dec 31, 2022 | 4.34 Mn |
| Sep 30, 2022 | 1.85 Mn |
| Dec 31, 2021 | 805,000.00 |